Safety of the Nocturnal Passy Muir Valve and Impact on Sleep Quality at an LTACH Setting

Tracheostomy Clinical Trial

Official title:

Assessing the Safety of the Nocturnal Passy Muir Valve and Its Impact on Sleep Quality in an LTACH Setting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06229639
• Other study ID #: 201512TAN
• Status: Completed
• Phase: N/A
• Start date: January 2016
• Est. completion date: February 2018

Study information

• Verified date: January 2024
• Source: Gaylord Hospital, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Limited research has been done to assess the safety of PMV use during sleep. One prospective study completed by Diez-Gross, et al in 2007 looked at 10 male subjects recorded on two consecutive nights, one night with PMV on and one night with PMV off. All recordings took place in a monitored setting. The variables studied included O2 saturation, apnea index, apnea - hypopnea index, and nursing reports. Conclusion was PMV use for one night in seriously ill tracheostomy patients was not associated with respiratory distress or cardiac issues.

Description:

Currently, the PMV has only been approved by the FDA for daytime use. As such, it is encouraged to remove speaking valves at night. However, there is minimal evidence indicating that the use of speaking valves during nighttime poses a significant risk. Studies focusing on the safety of the PMV for nocturnal use reported no significant effects on patients' well-being, including no significant oxygen desaturations or major cardiopulmonary events. This was shown in pediatric patients and adult patients admitted to an ICU. While promising, these findings are still limited, and additional evidence is needed to demonstrate the safety of nocturnal PMV use before larger studies can be conducted. It was anecdotally witnessed that patients frequently sleep during the day with the PMV in place, suffering no recourse to adverse events. The primary objective of this study was to determine if nocturnal PMV use can be considered safe within the long-term acute care hospital setting and its impact on sleep quality

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: February 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient has evidence of respiratory insufficiency requiring a tracheostomy tube without current need for assisted ventilation.

2. Patient will be continuously monitored with telemetry.

3. Patient satisfies criteria for the decannulation protocol and agrees to use the Passy Muir Valve during sleep.

4. Patient is able to follow directions following speech/language/cognitive evaluation or screening completed by the Speech-Language Pathologist and physician assessment.

5. Patient is at least 18 years old.

6. An informed consent is signed by patient or Power of Attorney (POA).

7. Patient is able to tolerate the PMV during the day for a minimum of 6 continuous hours

8. Patient has a maximum size #6 Shiley cuffless tracheostomy tube or equivalent.

Exclusion Criteria:

1. Patient identified at time of admission as requiring invasive long-term assisted ventilation.

2. Patient with documented or suspected upper airway obstruction and/or surgery or permanent tracheostomy tube.

3. Patient is quadriplegic (due to the inability for a quadriplegic patient to manually self-remove the valve in case of emergency).

4. Patient or POA failed to sign consent.

5. Pt has a severe cognitive impairment as determined by a formal cognitive-linguistic evaluation by a licensed Speech Language Pathologist.

6. Patient unable to meet criteria for decannulation protocol or has failed decannulation protocol within last two weeks.

Related Conditions & MeSH terms

• Tracheostomy

Intervention

Device:
• Passy Muir Valve

• Tracheostomy Plug

Locations

Country	Name	City	State
United States	Gaylord Hospital	Wallingford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Gaylord Hospital, Inc

Country where clinical trial is conducted

United States, 

References & Publications (14)

510(k) Premarket Notification. U.S. Food and Drug Administration. Accessed June 23, 2022. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K962714

Barraza GY, Fernandez C, Halaby C, Ambrosio S, Simpser EF, Pirzada MB, Islam S. The safety of tracheostomy speaking valve use during sleep in children: a pilot study. Am J Otolaryngol. 2014 Sep-Oct;35(5):636-40. doi: 10.1016/j.amjoto.2014.04.011. Epub 2014 May 4. Erratum In: Am J Otolaryngol. 2016 Sep-Oct;37(5):477. Islam S [added]. — View Citation

DuBose JR, Hadi K. Improving inpatient environments to support patient sleep. Int J Qual Health Care. 2016 Oct;28(5):540-553. doi: 10.1093/intqhc/mzw079. Epub 2016 Aug 10. — View Citation

Durbin CG Jr. Tracheostomy: why, when, and how? Respir Care. 2010 Aug;55(8):1056-68. — View Citation

Gross RD, Atwood C. R168: Safety of Tracheostomy Speaking Valve Use during Sleep. Otolaryngol Head Neck Surg. 2007;137(2_suppl):P209-P209. doi:10.1016/j.otohns.2007.06.505

Lian S, Teng L, Mao Z, Jiang H. Clinical utility and future direction of speaking valve: A review. Front Surg. 2022 Sep 8;9:913147. doi: 10.3389/fsurg.2022.913147. eCollection 2022. — View Citation

Liney T, Dawson R, Seth R, et al. Anxiety levels amongst patients with tracheostomies. British Journal of Anaesthesia. 2019;123(4):e504-e505. doi:10.1016/j.bja.2019.04.027

Martin JL, Fiorentino L, Jouldjian S, Josephson KR, Alessi CA. Sleep quality in residents of assisted living facilities: effect on quality of life, functional status, and depression. J Am Geriatr Soc. 2010 May;58(5):829-36. doi: 10.1111/j.1532-5415.2010.02815.x. — View Citation

O'Connor LR, Morris NR, Paratz J. Physiological and clinical outcomes associated with use of one-way speaking valves on tracheostomised patients: A systematic review. Heart Lung. 2019 Jul-Aug;48(4):356-364. doi: 10.1016/j.hrtlng.2018.11.006. Epub 2018 Dec 17. — View Citation

Passy V, Baydur A, Prentice W, Darnell-Neal R. Passy-Muir tracheostomy speaking valve on ventilator-dependent patients. Laryngoscope. 1993 Jun;103(6):653-8. doi: 10.1288/00005537-199306000-00013. — View Citation

Richards KC, O'Sullivan PS, Phillips RL. Measurement of sleep in critically ill patients. J Nurs Meas. 2000 Fall-Winter;8(2):131-44. — View Citation

Shuman AG, Duffy SA, Ronis DL, Garetz SL, McLean SA, Fowler KE, Terrell JE. Predictors of poor sleep quality among head and neck cancer patients. Laryngoscope. 2010 Jun;120(6):1166-72. doi: 10.1002/lary.20924. — View Citation

Silveira AR, Soki MN, Chone CT, Tah Y Ng R, Carvalho EG, Crespo AN. Brazilian tracheotomy speech valve: diaphragm pressure standardization. Braz J Otorhinolaryngol. 2009 Jan-Feb;75(1):107-10. doi: 10.1016/s1808-8694(15)30840-5. — View Citation

Winters B, Serpas D, Fullmer N, Hughes K, Kincaid J, Rosario ER, Schnakers C. Sleep Quality Should Be Assessed in Inpatient Rehabilitation Settings: A Preliminary Study. Brain Sci. 2023 Apr 25;13(5):718. doi: 10.3390/brainsci13050718. — View Citation

* Note: There are 14 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Heart rate	Measures the number of contractions of the heart per minute (bpm).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	Systolic Blood Pressure	Measures the pressure in your arteries when your heart beats (mmHg).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	Diastolic blood pressure	Measures the pressure in your arteries when your heart rests between beats (mmHg).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	Body Temperature	Measures the normal body temperature of participants (°F).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	O2	Oxygen saturation measures percentage of oxyhemoglobin in the blood (%).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	ETCO2	The level of carbon dioxide that is released at the end of an exhaled breath (mm Hg).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Primary	Respiratory Rate	Measures the breathing rate by number of breaths per minute (bpm).	Night 1 at 22:00, 2:00, 6:00 and night 2 at 22:00, 2:00, 6:00
Secondary	PCO2	The amount of carbon dioxide in the blood in the arterial blood gas measurements (mm Hg).	Morning after night 1 and morning after night 2
Secondary	PO2	The amount of oxygen in the blood by the arterial blood gas measurements (mm Hg).	Morning after night 1 and morning after night 2
Secondary	Bicarbonate	The amount of bicarbonate in the blood by the arterial blood gas measurements (mmol/L).	Morning after night 1 and morning after night 2
Secondary	Sleep Quality	This is measured by the Richards-Campbell Sleep Questionnaire, which is recorded on a 100 nm visual scale with higher scores indicating better sleep levels than lower scores.	Morning after night 1 and morning after night 2
Secondary	pH	The amount of pH in the blood measured by the arterial blood gas measurements.	Morning after night 1 and morning after night 2